{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=45", "query": { "condition": "Relapsed/Refractory", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 3666, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T08:18:51.436Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05983965", "title": "Study of Tazemetostat in Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2024-09-05", "completion_date": "2026-03-06", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05983965" }, { "nct_id": "NCT07630974", "title": "A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Ifinatamab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 134, "start_date": "2026-07-06", "completion_date": "2031-08-17", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 15, "location_summary": "Los Angeles, California • Aurora, Colorado • St. Petersburg, Florida + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630974" }, { "nct_id": "NCT04081259", "title": "LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "LY3214996", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-07-15", "completion_date": "2023-08-26", "has_results": false, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04081259" }, { "nct_id": "NCT00112723", "title": "Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Multiple Myeloma", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2005-12", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112723" }, { "nct_id": "NCT01969682", "title": "A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "ABT-199", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-04", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-26", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01969682" }, { "nct_id": "NCT06207123", "title": "A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Leukemia", "Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "LP-118", "type": "DRUG" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2024-09-13", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 2, "location_summary": "Chicago, Illinois • Rochester, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06207123" }, { "nct_id": "NCT06450041", "title": "NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Universal Donor (UD) TGFβi NK Cells", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Dinutuximab", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 62, "start_date": "2024-12-16", "completion_date": "2038-12", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06450041" }, { "nct_id": "NCT02573896", "title": "Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Dinutuximab", "type": "DRUG" }, { "name": "NK Cells", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 13, "start_date": "2019-01-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573896" }, { "nct_id": "NCT04892446", "title": "Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2021-11-09", "completion_date": "2024-04-25", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 16, "location_summary": "Tucson, Arizona • La Jolla, California • Palo Alto, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04892446" }, { "nct_id": "NCT00474188", "title": "A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "CC-5013 (lenalidomide)", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2007-05", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2009-09-02", "last_synced_at": "2026-11-14T08:18:51.436Z", "location_count": 19, "location_summary": "Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474188" } ] }